A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New SARS-CoV-2 Variants of Concern
Description
Emerging variants of SARS-CoV-2 possess mutations that prevent antibody therapeutics from maintaining anti-viral binding and neutralizing efficacy. Monoclonal antibodies (mAb) shown to neutralize Wuhan-Hu-1 SARS-CoV-2 (ancestral) strain have reduced